Avalo Therapeutics Files 8-K on Security Holder Vote

Ticker: AVTX · Form: 8-K · Filed: Jun 17, 2025 · CIK: 1534120

Avalo Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyAvalo Therapeutics, INC. (AVTX)
Form Type8-K
Filed DateJun 17, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, shareholder-vote

Related Tickers: AVTX

TL;DR

AVTX is calling a shareholder vote, big decisions ahead.

AI Summary

On June 17, 2025, Avalo Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is submitting matters to a vote of its security holders. No specific details regarding the nature of the vote or the matters to be voted upon were provided in the excerpt.

Why It Matters

This filing signals that Avalo Therapeutics is seeking shareholder approval for a significant decision, which could impact the company's future direction and shareholder value.

Risk Assessment

Risk Level: medium — The filing indicates a vote by security holders, which could lead to significant corporate actions that carry inherent risks.

Key Numbers

Key Players & Entities

FAQ

What specific matters will be presented for a vote by Avalo Therapeutics' security holders?

The provided excerpt does not specify the exact matters to be voted upon by security holders.

When is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is June 17, 2025.

What is the principal executive office address for Avalo Therapeutics, Inc.?

The principal executive office is located at 1500 Liberty Ridge Drive, Suite 321, Wayne, Pennsylvania 19087.

What was Avalo Therapeutics, Inc. formerly known as?

Avalo Therapeutics, Inc. was formerly known as Cerecor Inc.

Under which section of the Securities Exchange Act is this Current Report filed?

This Current Report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 17, 2025 regarding Avalo Therapeutics, Inc. (AVTX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing